Retatrutide (LY3437943): Triple-Hormone Receptor Agonist Research Guide

Retatrutide (code name LY3437943) is a once-weekly subcutaneous peptide developed by Eli Lilly and Company that simultaneously activates three metabolically relevant receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This triple pharmacology places retatrutide in a distinct class beyond dual GLP-1/GIP agonists such as tirzepatide.

The pivotal Phase 2 publications in the New England Journal of Medicine and The Lancet, both appearing in August 2023, reported weight reductions and glycemic improvements that positioned retatrutide as one of the most potent investigational agents for obesity and type 2 diabetes (T2D) documented at that stage of clinical development (PMID: 37366315; PMID: 37385280).

Molecular Characteristics

Retatrutide is a 36-amino acid acylated peptide structurally derived from a modified glucagon sequence with elements that confer GLP-1R and GIPR agonism. Eli Lilly incorporated a C18 fatty diacid moiety via a hydrophilic linker, extending the half-life through albumin binding and enabling once-weekly subcutaneous dosing.

Key Properties

• Class: Triple GLP-1R/GIPR/GCGR agonist (acylated peptide)
• Molecular targets: GLP-1 receptor, GIP receptor, glucagon receptor
• Half-life: Approximately 6 days (supports weekly dosing)
• Route: Subcutaneous injection, once weekly
• Developer: Eli Lilly and Company
• INN: Retatrutide; internal code LY3437943

The glucagon receptor component distinguishes retatrutide from tirzepatide. GCGR agonism increases hepatic glucose production in isolation, but in the context of concurrent GLP-1R agonism (which stimulates insulin secretion and suppresses glucagon), net glycemic effects remain controlled. GCGR agonism additionally increases energy expenditure and promotes hepatic fat oxidation, adding a mechanism not present in dual agonists.

Mechanism of Action

Retatrutide acts at three class B1 G protein-coupled receptors that each signal primarily through Gs-mediated cyclic AMP (cAMP) elevation.

flowchart TD
    RET["Retatrutide\n(LY3437943)"]

    subgraph Receptors["Target Receptors"]
        GLP1R["GLP-1 Receptor\n(GLP1R)"]
        GIPR["GIP Receptor\n(GIPR)"]
        GCGR["Glucagon Receptor\n(GCGR)"]
    end

    RET -->|Agonist| GLP1R
    RET -->|Agonist| GIPR
    RET -->|Agonist| GCGR

    subgraph Pancreas["Pancreas"]
        INS["Increased insulin\nsecretion (glucose-dependent)"]
        GLUC_SUP["Glucagon\nsuppression"]
    end

    subgraph Hypothalamus["Hypothalamus / Brainstem"]
        SAT["Satiety signaling\nreduced food intake"]
    end

    subgraph Liver["Liver"]
        HGP["Hepatic glucose\nproduction modulation"]
        FAT["Increased fat\noxidation"]
    end

    subgraph Adipose["Adipose Tissue"]
        LIPOL["Lipolysis\nstimulation via GIPR"]
    end

    subgraph Energy["Energy Balance"]
        EE["Increased energy\nexpenditure via GCGR"]
    end

    GLP1R --> INS
    GLP1R --> GLUC_SUP
    GLP1R --> SAT
    GIPR --> INS
    GIPR --> LIPOL
    GCGR --> HGP
    GCGR --> FAT
    GCGR --> EE

    INS --> WL["Weight loss and\nglycemic improvement"]
    GLUC_SUP --> WL
    SAT --> WL
    FAT --> WL
    EE --> WL
    LIPOL --> WL

GLP-1 receptor agonism drives glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon from alpha cells, slows gastric emptying, and generates central satiety signals via the nucleus tractus solitarius and hypothalamic circuits.

GIP receptor agonism potentiates glucose-stimulated insulin secretion and acts at adipose tissue and bone. In the context of obesity pharmacotherapy, GIPR activation appears to amplify weight-lowering effects when combined with GLP-1R agonism, consistent with data from tirzepatide trials and confirmed in retatrutide’s Phase 2 program.

Glucagon receptor agonism is the pharmacological feature unique to retatrutide among approved or late-stage weight-loss agents. GCGR agonism increases hepatic glucose output and raises cAMP in hepatocytes, promoting fatty acid oxidation. In rodent models, GCGR co-agonism on top of GLP-1R activation produces additive reductions in body weight and liver fat content. A 2026 mouse study in Molecular Metabolism (PMID: 41997446) confirmed that combined GIPR and GCGR co-agonism restores normal body weight in obese rodents, supporting the mechanistic rationale for the triple combination.

Discovery and Development History

Eli Lilly’s internal medicinal chemistry program built on the company’s experience with tirzepatide (LY3298176), a GLP-1R/GIPR dual agonist. Incorporating glucagon receptor pharmacology required careful balancing: unmodified GCGR agonism raises blood glucose and can cause hyperglycemia, but the combined GLP-1R and GIPR insulinotropic effects counteract this when all three activities are calibrated. Lilly’s preclinical program demonstrated that a balanced triple agonist reduces body weight and improves liver histology in animal models of obesity and non-alcoholic steatohepatitis (NASH) without adverse hyperglycemic effects.

Development Timeline

• 2019: NCT03841630 first-in-human single ascending dose safety study completed in healthy participants
• 2020-2021: Phase 1 multiple ascending dose and PK characterization (NCT05959096, NCT05548231)
• 2022: Phase 2 obesity trial (NCT04881760) and Phase 2 T2D trial (NCT04867785) underway
• 2023 (Jun): Rosenstock et al., Phase 2 T2D results published in The Lancet (PMID: 37385280; DOI: 10.1016/S0140-6736(23)01053-X)
• 2023 (Aug): Jastreboff et al., Phase 2 obesity results published in NEJM (PMID: 37366315; DOI: 10.1056/NEJMoa2301972)
• 2023 (Oct): Authors’ reply clarifying trial design details (PMID: 37888927)
• 2024-2025: TRIUMPH Phase 3 program initiated across obesity, T2D, and cardiovascular disease populations
• 2025-2026: Additional Phase 2 mechanistic and special-population studies ongoing

Clinical Trial Programs

Phase 1: First-in-Human and Pharmacokinetics

NCT03841630 was the first Phase 1 safety study of LY3437943, administering single ascending doses to healthy participants. The study established the initial safety and PK parameters that guided Phase 2 dose selection. NCT05959096 subsequently examined multiple dosing in participants with a high BMI, extending safety and PK characterization to the obesity target population. NCT05548231 assessed PK in Chinese participants with obesity or overweight, important for regional regulatory submissions.

NCT05916560 evaluated LY3437943 in participants with impaired and normal liver function, and NCT06808802 examined the effect of retatrutide on metoprolol pharmacokinetics to characterize the drug-drug interaction potential via gastric emptying effects on co-administered oral medications.

Phase 2: Obesity

NCT04881760 was a randomized, double-blind, placebo-controlled Phase 2 dose-ranging trial in 338 adults with obesity (BMI 30-50 kg/m2) or overweight (BMI 27-30 kg/m2 with at least one weight-related comorbidity) without diabetes, treated over 48 weeks with once-weekly subcutaneous doses of 1 mg, 4 mg, 8 mg, or 12 mg retatrutide.

Results published in the NEJM (PMID: 37366315) demonstrated a dose-dependent reduction in body weight:

• 1 mg: Mean weight reduction approximately 8.7%
• 4 mg: Mean weight reduction approximately 17.3%
• 8 mg: Mean weight reduction approximately 22.8%
• 12 mg: Mean weight reduction approximately 24.2% at 48 weeks

The 12 mg cohort had not reached a plateau at 48 weeks, suggesting continued weight loss with extended treatment. These results exceeded the weight reductions reported in comparably designed Phase 2 trials for tirzepatide and semaglutide, though cross-trial comparisons carry significant methodological caveats. Larger total weight reduction can also change lean-mass accounting, so body-composition outcomes require separate interpretation. Adverse events were predominantly gastrointestinal: nausea, vomiting, constipation, and decreased appetite, consistent with the GLP-1R agonist class.

Phase 2: Type 2 Diabetes

NCT04867785 was a randomized, double-blind, placebo- and active-controlled Phase 2 trial in 281 adults with T2D across the United States. Three doses of retatrutide (2 mg, 4 mg, 12 mg once weekly) were compared with dulaglutide 1.5 mg and placebo over 36 weeks.

Results published in The Lancet (PMID: 37385280; DOI: 10.1016/S0140-6736(23)01053-X) demonstrated:

• HbA1c reduction at 12 mg: Mean -2.02 percentage points from baseline versus +0.53 pp for placebo
• Fasting glucose: Significant reduction across all doses
• Body weight at 12 mg: Mean reduction approximately 16.9% at 36 weeks
• Lipids and blood pressure: Improvement across lipid fractions and systolic blood pressure

The active comparator (dulaglutide 1.5 mg) served as a reference for HbA1c outcomes. Retatrutide at all three doses outperformed dulaglutide on weight reduction, reflecting the additional GIP and glucagon receptor contributions.

Phase 2: Special Populations

NCT06297603 (TRANSCEND-T2D-3) evaluates retatrutide versus placebo in T2D patients with moderate or severe renal impairment on basal insulin, providing data for a population frequently excluded from pivotal trials.

NCT06982846 examines the response of T2D participants on retatrutide to experimentally induced hypoglycemia, characterizing how glucagon receptor agonism modifies hypoglycemic counter-regulation.

NCT06662383 directly compares retatrutide to tirzepatide in adults with obesity, providing head-to-head pharmacological data (active, not yet reporting as of April 2026).

Phase 3: TRIUMPH Program

Eli Lilly is conducting the TRIUMPH Phase 3 program, spanning obesity, T2D, and cardiovascular risk populations. As of April 2026, several TRIUMPH trials are active or recruiting:

NCT05882045 evaluates retatrutide in participants with obesity and established cardiovascular disease. This study is relevant to future cardiovascular outcomes trial design and will characterize safety in a higher-risk population.

NCT07467447 is a placebo-controlled Phase 3 trial in participants with obesity or overweight, representing one of the core TRIUMPH weight-management trials currently recruiting.

Phase 3 programs typically mirror the regulatory package structure established by tirzepatide and semaglutide: separate trials for obesity without diabetes, T2D with excess body weight, cardiovascular outcomes, and special populations.

Primary Research Areas

Obesity and Weight Management

Retatrutide’s weight-reduction program is its highest-profile research area. The Phase 2 NEJM trial established a dose-response relationship with weight reduction at the highest registered dose exceeding 24% at 48 weeks, surpassing the typical 15-22% reductions reported for tirzepatide 15 mg and semaglutide 2.4 mg in their respective Phase 3 programs.

The glucagon receptor component adds an energy expenditure dimension absent from GLP-1-only or dual GLP-1/GIP agents. GCGR activation increases thermogenesis and hepatic fat oxidation, which may contribute to retatrutide’s greater weight-lowering effect relative to dual agonists. The Phase 3 program will determine whether this translates to superior outcomes in adequately powered, longer-duration trials.

Type 2 Diabetes and Glycemic Control

The T2D Phase 2 data (PMID: 37385280) demonstrated HbA1c reductions in the range achievable with established injectables, while simultaneously producing weight reductions of a magnitude typically associated only with bariatric surgery. For T2D patients where obesity drives much of the metabolic dysfunction, a compound addressing both glycemia and body weight via a single weekly injection represents a distinct clinical proposition.

The TRANSCEND-T2D-3 trial (NCT06297603) extends this into the renal impairment population, an important subgroup because GLP-1 receptor agonists are frequently used in T2D patients with CKD, but renal PK changes must be characterized.

Non-Alcoholic Fatty Liver Disease (NAFLD/MASH)

Glucagon receptor agonism promotes hepatic fat oxidation. In rodent and hamster models of metabolic-associated steatohepatitis (MASH), retatrutide reduced liver fat content, hepatic inflammation, and fibrosis markers more than GLP-1-only agents (PMID: 41741376; Briand et al., Obesity, 2026). A 2026 multi-omics analysis further showed that retatrutide alleviates adipose tissue fibrosis through metabolic reprogramming, a mechanism relevant to MASH pathophysiology (PMID: 41964043).

These preclinical and translational findings position retatrutide as a candidate for MASH trials, a disease area where tirzepatide has already received FDA Breakthrough Therapy designation.

Cardiovascular Risk Reduction

Obesity and T2D are major cardiovascular risk factors. NCT05882045 evaluates retatrutide specifically in patients with established cardiovascular disease. The Phase 2 T2D data showed improvements in blood pressure and lipid profiles. Whether retatrutide produces cardiovascular event reduction analogous to that demonstrated for semaglutide (LEADER, SUSTAIN-6, SELECT trials) will require dedicated cardiovascular outcomes trial data.

A 2026 review of glucagon receptor agonists and their metabolic outcomes (PMID: 41787737) placed retatrutide in the context of a broader class of agents and summarized the theoretical cardiovascular benefits arising from each receptor contribution.

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Multiple 2026 reviews covering pharmacologic treatment of MASLD examined retatrutide’s mechanism and emerging preclinical data (PMID: 41831086; PMID: 41823054). The triple-receptor mechanism addressing hepatic fat oxidation, adipose tissue remodeling, and systemic insulin resistance provides a broad mechanistic rationale for MASLD research.

Structural and Mechanistic Research

Retatrutide’s balanced triple-receptor agonism required specific peptide engineering. A single sequence must activate three structurally related but pharmacologically distinct GPCRs. The glucagon superfamily of peptides (glucagon, GLP-1, GIP) share structural homology at their N-terminal regions, enabling retatrutide’s single-sequence design.

The 2026 Molecular Metabolism study (PMID: 41997446) specifically examined how simultaneous GIPR and GCGR co-agonism restores weight homeostasis in obese rodent models, providing mechanistic insight into the glucagon receptor contribution independent of GLP-1R effects.

Comparison with Related Compounds

Retatrutide’s triple mechanism is shared by no approved compound as of April 2026. The closest structural and mechanistic comparator is mazdutide (IBI362), a dual GLP-1R/GCGR agonist lacking GIPR activity, which is in late-stage development in China. Among Lilly’s own portfolio, the head-to-head NCT06662383 trial comparing retatrutide directly to tirzepatide will provide the clearest within-class comparison.

Pharmacokinetics Overview

Retatrutide’s fatty acid acylation produces a plasma half-life of approximately six days, consistent with once-weekly dosing. Phase 1 studies across healthy participants (NCT03841630) and obese participants (NCT05959096) characterized the PK profile. Special population studies have addressed renal impairment (NCT06297603), hepatic impairment (NCT05916560), and ethnic variation (NCT05548231 in Chinese participants).

A completed drug-drug interaction study (NCT06808802) examined the effect of retatrutide on metoprolol, a narrow therapeutic index oral drug sensitive to changes in gastric emptying. This is a standard characterization for GLP-1 class agents because delayed gastric emptying can alter oral drug absorption. Full pharmacokinetic parameters including volume of distribution, clearance, and population PK modeling will be covered in the Retatrutide Pharmacokinetics page.

Safety Overview

The Phase 2 safety profile of retatrutide is consistent with the GLP-1 receptor agonist class. The most common adverse events in the obesity Phase 2 trial (PMID: 37366315) were:

• Nausea (most frequent; typically early, transient, and mild-to-moderate)
• Vomiting
• Constipation
• Decreased appetite
• Diarrhea

Dose-dependent rates of GI adverse events were observed, with the highest rates at 8 mg and 12 mg doses. Discontinuation due to adverse events was reported across dose groups. Heart rate increased modestly, consistent with the known pharmacology of GLP-1R and GCGR agonism. No unexpected safety signals were identified in the Phase 2 program.

The hypoglycemia characterization trial (NCT06982846) will provide formal data on counter-regulatory hormone responses to hypoglycemia in retatrutide-treated T2D patients, a relevant safety consideration given that GCGR agonism may alter glucagon counter-regulation.

A comprehensive adverse event analysis, discontinuation rates, and emerging Phase 3 safety data are covered in the Retatrutide Safety page.

Dose-Response Relationship

Phase 2 data established a clear dose-response for both weight reduction and GI adverse event frequency. The 12 mg once-weekly dose produced the greatest weight reduction and HbA1c reduction, with a plateau not yet reached at 48 weeks in the obesity trial. The 4 mg dose showed an intermediate profile that may be relevant for patients with lower tolerability. Eli Lilly’s Phase 3 program is expected to use a dose escalation schedule, as employed for tirzepatide, to improve tolerability.

Full dose-response curves and their clinical implications are covered in the Retatrutide Dose-Response page.

Mechanism of Action Detail

The molecular pharmacology of retatrutide at GLP-1R, GIPR, and GCGR, including receptor binding kinetics, bias signaling, and the central pathways mediating satiety and energy expenditure, are covered in the Retatrutide Mechanism page.

Clinical Evidence Summary

Quantitative Phase 2 outcomes for weight reduction, HbA1c, blood pressure, lipids, and body composition, together with available Phase 3 interim data, are covered in the Retatrutide Evidence page.

Related Research

• Retatrutide Mechanism, GLP-1R, GIPR, and GCGR pharmacology and central energy balance pathways
• Retatrutide Evidence, Phase 2 quantitative outcomes and Phase 3 updates
• Retatrutide Pharmacokinetics, half-life, population PK, and drug interactions
• Retatrutide Dose-Response, dose escalation, therapeutic window, and tolerability
• Retatrutide Safety, adverse event profile and special population safety
• Cagrilinitide Research, amylin-class triple mechanism agent from Novo Nordisk
• AMPK Pathway, downstream metabolic signaling node shared across anti-obesity mechanisms
• Mitochondrial Biogenesis, energy expenditure pathway relevant to GCGR-mediated thermogenesis

Latest research updates

• Semaglutide Resolves NASH in 63% of Patients in Phase 3 ESSENCE Trial (NCT04822181) — 2026-04-17